Wexford Capital LP United Therapeutics Corp Transaction History

Wexford Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$174.81 - $241.14 $279,870 - $386,065	-1,601 Reduced 28.58%	4,000 $943,000
Q1 2022 May 13, 2022	SELL	$166.16 - $213.96 $398,617 - $513,290	-2,399 Reduced 29.99%	5,601 $1.01 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $368,640 - $432,160	-2,000 Reduced 20.0%	8,000 $1.73 Million
Q1 2021 May 13, 2021	BUY	$153.94 - $174.85 $384,850 - $437,125	2,500 Added 33.33%	10,000 $1.67 Million
Q4 2020 Feb 16, 2021	BUY	$101.87 - $151.79 $764,025 - $1.14 Million	7,500 New	7,500 $1.14 Million

676

42.1M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.